Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Trevena in a research note on Tuesday, April 2nd.

Trevena Stock Performance

Shares of TRVN stock opened at $0.43 on Wednesday. The firm has a market capitalization of $7.86 million, a PE ratio of -0.14 and a beta of 1.11. The company has a debt-to-equity ratio of 8.35, a quick ratio of 4.66 and a current ratio of 4.66. Trevena has a 1 year low of $0.30 and a 1 year high of $1.83. The stock has a fifty day moving average of $0.45 and a two-hundred day moving average of $0.56.

Trevena (NASDAQ:TRVN) last announced its earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The company had revenue of ($0.08) million for the quarter, compared to analysts’ expectations of $0.09 million. As a group, research analysts expect that Trevena will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC bought a new position in Trevena, Inc. (NASDAQ:TRVN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned about 0.32% of Trevena as of its most recent SEC filing. Hedge funds and other institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.